Survanta 8ml Injection
$198,00
$189,00
Survanta 8 ml (Beractant 200 mg Injection) is a pulmonary surfactant medicine used to prevent and treat Respiratory Distress Syndrome (RDS) in premature newborns with a birth weight of 700 g or more. Extracted from bovine lungs, Beractant helps newborns’ lungs function properly by reducing surface tension and improving breathing efficiency. Survanta Injection is vital for preterm infants—especially those born before 32 weeks—who are at high risk of RDS and require endotracheal intubation for stabilization. Manufactured under strict quality standards, this medication supports neonatal respiratory care in critical situations. Parents and healthcare professionals should use it only under medical supervision. Common side effects may include noisy breathing, feeding difficulties, or mild bleeding around the endotracheal tube. Always consult a qualified neonatologist before use and report any signs of allergy or adverse reaction to Beractant.
數量
Active Pharmaceutical Ingredient
Beractant
Uses
Prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants with a birth weight of 700 g or more. Helps reduce surface tension in the lungs, allowing easier breathing and improved oxygen exchange. Supports lung function in preterm newborns, especially those born before 32 weeks of gestation. Used in neonatal intensive care units (NICUs) as part of respiratory support for infants requiring endotracheal intubation and mechanical ventilation. Plays a crucial role in stabilizing critically ill premature babies at high risk of developing RDS. Aids in reducing the need for prolonged respiratory support and improving overall survival rates in neonates.
Benefits
Restores normal lung function: Replaces the missing or inactive surfactant in premature infants’ lungs, enabling proper breathing. Prevents and treats Respiratory Distress Syndrome (RDS): Reduces the severity and complications of RDS in preterm newborns. Improves oxygenation and ventilation: Enhances gas exchange and lung compliance, supporting effective respiration. Reduces the need for mechanical ventilation: Helps stabilize infants faster, potentially shortening NICU stay and ventilation time. Clinically proven and safe: Manufactured under stringent quality standards and widely used in neonatal care worldwide. Supports early survival and recovery: Improves the overall outcome of premature infants, promoting healthier development during the critical early stage.
Side Effects
As with all medicines, Servant Injection 150 mg may cause side effects which do not require medical attention and which will disappear as your body adjusts to the medicine. If they persist or you're concerned about them, tell your doctor.
Most Common Side Effects
Noisy or irregular breathing after administration
Mild bleeding or discharge around the endotracheal tube
Feeding difficulties or reflux
Temporary slowing of heart rate (bradycardia)
Oxygen desaturation (brief drop in oxygen levels)
Common Side Effects
Lung infection (pneumonia)
Pulmonary hemorrhage (bleeding in the lungs)
Blockage of the breathing tube (endotracheal obstruction)
Allergic reaction to Beractant (rash, swelling, difficulty breathing)
How To Use
Survanta is administered only by trained healthcare professionals in a hospital or neonatal intensive care setting. The medication is given directly into the lungs through an endotracheal tube after the infant has been intubated and stabilized. The dose and timing depend on the newborn’s weight, gestational age, and respiratory condition. It may be used as a preventive dose shortly after birth in high-risk preterm infants, or as a rescue treatment for those already showing signs of Respiratory Distress Syndrome (RDS). During and after administration, the infant’s breathing, heart rate, and oxygen levels are closely monitored by the medical team. Repeated doses may be given if symptoms persist, always under strict neonatal supervision.
Safety Advice
Survanta should be administered only under the supervision of a qualified neonatologist or healthcare professional experienced in managing premature infants with Respiratory Distress Syndrome (RDS). It must be used strictly within a hospital or neonatal intensive care unit (NICU) equipped for endotracheal intubation and continuous monitoring. Careful observation of the infant’s heart rate, oxygen saturation, and lung function is essential during and after administration. The product should not be shaken or diluted, and any unused portion should be discarded immediately after use. Parents and caregivers should be informed that Survanta is not for home use and should never be self-administered. Report any signs of allergic reaction, persistent breathing difficulty, or unusual skin discoloration to the attending physician promptly. Proper handling, storage (as per label instructions), and disposal protocols must be followed to maintain product safety and sterility.